Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Anti-FLT3 Chimeric Antigen Receptor-redirected T Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT06786533 is registered in ClinicalTrials.gov with Hemogenyx Pharmaceuticals LLC as lead sponsor.

NCT NCT06786533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06786533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Anti-FLT3 Chimeric Antigen Receptor-redirected T Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
Hemogenyx Pharmaceuticals LLC
Phase
Phase 1
Overall status
Recruiting
Start date
January 23, 2025
Completion date
January 31, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia (r/r aml)